[2] Peng L, Sferruzza G, Yang L, Zhou L, Chen S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol. 2024;21(10):1089-1108. F: 21.8 [3] Bahramloo M, Shahabi SA, Kalarestaghi H, et al. CAR-NK cell therapy in AML: Current treatment, challe...
[2]CAR-NKT cell therapy shows promising results against neuroblastoma in phase 1 clinical trial.https://medicalxpress.com/news/2023-05-car-nkt-cell-therapy-results-neuroblastoma.html [3] Nelson A, Lukacs JD, Johnston ...
参考资料: https://www.onclive.com/view/car-nkt-cell-therapy-can-induce-complete-remissions-in-pediatric-neuroblastoma 全球肿瘤医生网提醒 国内细胞免疫治疗技术,包括cart细胞,树突细胞疫苗,NK细胞,TILs细胞,TCR t细胞治疗,癌症疫苗等技术均处于临...
[2] Peng L, Sferruzza G, Yang L, Zhou L, Chen S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol. 2024;21(10):1089-1108. F: 21.8 [3] Bahramloo M, Shahabi SA, Kalarestaghi H, et al. CAR-NK cell therapy in AML: Current treatment, challe...
Today, cancer treatment is one of the fundamental problems facing clinicians and researchers worldwide. Efforts to find an excellent way to treat this illness continue, and new therapeutic strategies are developed quickly. Adoptive cell therapy (ACT) is
Although CAR-T cell therapy has achieved remarkable success in treating certain cancers, its limitations necessitate exploring alternative approaches. In this context, CAR-NKT cells emerge as a promising approach for overcoming these challenges, potentially achieving safer and more effective immunotherapies....
①CAR-NK细胞的靶抗原:CAR-NK细胞具有通过CAR依赖性途径和天然机制(ADCC)对癌细胞发挥细胞毒作用的独特能力,因此可以改变CAR的设计,利用NK细胞的天然细胞毒性途径,从而降低对可能表达靶抗原的正常细胞造成损伤的风险。例如,可以设计缺乏共刺激结构域的CAR,使CAR-NK细胞主要利用其先天性细胞毒性能力,同时最大限度地减少...
并且这种疗法有治疗所有实体肿瘤的潜力! 随着更多治疗方案的发展,晚期肿瘤患者将迎来更多治疗选择和希望,我们期待人类攻克癌症的那一天早日到来。 参考资料: https://www.onclive.com/view/car-nkt-cell-therapy-can-induce-complete-remissions-in-pediatric-neuroblastoma...
[3] Bahramloo M, Shahabi SA, Kalarestaghi H, et al. CAR-NK cell therapy in AML: Current treatment, challenges, and advantage. Biomed Pharmacother. 2024;177:117024. IF: 6.9 [4] Lu J, Ma Y, Li Q, Xu Y, Xue Y, Xu S. CAR Macrophages: a promising novel immunotherapy for solid ...
allogeneic engineered CAR-NKT cell therapy,” said Kevin S. Boyle, Sr., Chief Executive Officer of Kuur. “The clinical activity and safety data from both clinical trials are encouraging for the potential of our innovative CAR-NKT cell platform to create effective therapies f...